Expanded Double Capacity Approved for Orano Versa-Pac 55 Transport Package for LEU+ and HALEU
New lightweight internal shoring basket doubles shipping capacity.
BETHESDA, Md., September 5, 2023 – Orano’s new High-Capacity Basket (HCB) for its Versa-Pac VP-55 enriched uranium transport package obtained approval from the Nuclear Regulatory Commission (NRC).
The HCB allows two 5-inch-diameter pipe containers to be secured inside a VP-55 package, instead of only one. At the maximum length of 21 inches, each pipe can be filled to capacity or hold two standard two-liter or three 850-milliliter plastic shipping bottles of material.
Orano’s VP-55 Type AF package was specifically designed and licensed to meet the anticipated increasing need for transporting 10% low-enriched uranium (LEU+) and up to 20% high-assay low-enriched uranium (HALEU) material fueling a growing number of advanced reactor designs.
“Based on our decades of nuclear fuel cycle expertise, Orano is increasingly involved in helping develop the advanced reactor supply chain with innovations and enhancements to our products and services,” said Amir Vexler, CEO of Orano USA. “Doubling the capacity of our versatile VP-55 package creates immediate value for customers shipping a variety of nuclear materials. We are excited to support the development of advanced reactors, which this package would enable.”
The Versa-Pac is licensed for shipment of TRISO fuel, uranium oxides, uranium metal, uranyl nitrate crystals and other uranium compounds such as uranium carbides, uranyl fluorides and uranyl carbonates, uranium hexafluoride, and thorium.
Orano USA is an active partner supporting advanced reactor developers with its decades of expertise designing, licensing, and fabricating radioactive material transport packages for fresh nuclear fuel, used fuel, reprocessed fuel, and decommissioning waste.
Download this press release.
About Orano USA: Orano USA, a regional subsidiary of Orano, is a leading supplier of advanced reactor services, nuclear fuel materials, used fuel management, decommissioning, decontamination, and radwaste treatment solutions to U.S. commercial and federal customers. Orano USA, through its subsidiary Orano Med in Texas, is also developing cancer treatments using targeted radio-immunotherapy, with its first drug currently in FDA-authorized clinical trials.
The HCB allows two 5-inch-diameter pipe containers to be secured inside a VP-55 package, instead of only one. At the maximum length of 21 inches, each pipe can be filled to capacity or hold two standard two-liter or three 850-milliliter plastic shipping bottles of material.
Orano’s VP-55 Type AF package was specifically designed and licensed to meet the anticipated increasing need for transporting 10% low-enriched uranium (LEU+) and up to 20% high-assay low-enriched uranium (HALEU) material fueling a growing number of advanced reactor designs.
“Based on our decades of nuclear fuel cycle expertise, Orano is increasingly involved in helping develop the advanced reactor supply chain with innovations and enhancements to our products and services,” said Amir Vexler, CEO of Orano USA. “Doubling the capacity of our versatile VP-55 package creates immediate value for customers shipping a variety of nuclear materials. We are excited to support the development of advanced reactors, which this package would enable.”
The Versa-Pac is licensed for shipment of TRISO fuel, uranium oxides, uranium metal, uranyl nitrate crystals and other uranium compounds such as uranium carbides, uranyl fluorides and uranyl carbonates, uranium hexafluoride, and thorium.
Orano USA is an active partner supporting advanced reactor developers with its decades of expertise designing, licensing, and fabricating radioactive material transport packages for fresh nuclear fuel, used fuel, reprocessed fuel, and decommissioning waste.
Download this press release.
About Orano USA: Orano USA, a regional subsidiary of Orano, is a leading supplier of advanced reactor services, nuclear fuel materials, used fuel management, decommissioning, decontamination, and radwaste treatment solutions to U.S. commercial and federal customers. Orano USA, through its subsidiary Orano Med in Texas, is also developing cancer treatments using targeted radio-immunotherapy, with its first drug currently in FDA-authorized clinical trials.